Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With an OM deal in the works along with "20+" Publications of viruses that Brilacidin obliterated some of you people think IPIX is only going to .20 to .30?
That actually makes us laugh.
Here Today How high do you think the share price will go after the Publications of the 20+ virus results? Tic Toc Tic Toc
Here Today
Member Level
Monday, November 08, 2021 7:59:24 PM
Re: None
Post#
382845
of 390542
I SEE a HUGE MOVE along with a TON of actual National Media attention once these results are announced!!!!
“The Company is also pleased to report Brilacidin has been shipped to two academic laboratories for planned in vitro testing of Brilacidin in over 20 acutely infectious viruses, including Ebola, Marburg, Nipah, West Nile and Zika, through a collaboration with U.S. government scientists. The goal of this testing is to further inform the spectrum of Brilacidin's antiviral properties.”
Pete Payer Analysis has nothing to do with a path forward. It pertains to costs for B-OM. How much will Medicare/Medicaid and Insurance companies be willing to pay for B-OM treatment. Apparently Pharma's and Leo don't agree so an independent analysis was done to please all. We (for LR) are just waiting on final report.
Payer Analysis is complete. Report being written as we type this.
IMO All signs are pointing to a definite Phase 3 for B-OM being run by someone other than IP. Leo just has to decide which one of the Pharma's he chooses to go with after the "Independent Payer Analysis" is completed if it hasn't already. Does he go with The most upfront money? The most Royalties? Largest Milestone Payments? Decisions Decisions.
Ya gotta love the new "Business Development Director". Excitement is back!
IMO Leo would not be running the "Payer Analysis" with Medicaid/Medicare/Insurance companies for B-OM if there wasn't a substantial deal in the works. Nice to have a few pharma's wanting to deal for Phase 3 ready B-OM. May the most dead presidents win!
The Squalas investment is a long term investment. 2-3 years before the 510(k) is filed. The new Business Development Director was hired to make some Brilacidin deals now. They had nothing to do with the Squalas Medical stake.
Just remember the letters OM:)
I know many of you think Leo is an idiot but he is far from it.
MackG you couldn't be more right. The IPIX Business Development Director was hired for their expertise in deal making and Big Pharma connections. The deal will have the IPIX msg board buzzing for weeks or maybe it will just finally quiet the board.
Does anybody know how long it takes to perform a "Payer Analysis"?
I imagine it can't be very long.
I know it's been at least 3 weeks since a company was hired by Leo that specializes in this. Hopefully it will be done real soon if not already completed.
Looks like a few pharma companies have different numbers on what Medicaid, Medicare and Insurance companies will pay
for Brilacidin's treatment of OM. I guess it's just all part of getting a deal done . I'm sure the "Payer Analysis" is being done at the request of the new "Business Development Director" to satisfy all interested parties. IMO a deal is near for OM. Very near.
The new hire was given a $100,000 signing bonus and $170,000+ salary.
These are the types of numbers given to a Business Development Director in Big Pharma. At least that's what they pay at GSK and Merck and that's a fact!
IMO news this month concerning a deal of some sorts.
IMO we see a term sheet in the next few weeks. The Business Development hire may be the smartest move Leo has ever made besides grabbing Brilacidin for $5m. I'm sure the hire has many Big Pharma connections. They all know one another. Time to start moving that decimal point to the right.
MackG I agree. Look for all heck to break loose very soon in a very positive way.
The new hire's background is "Business Development" not Product development as I mistakenly posted previously. He was brought in for his expertise in deal making.
IMO it's almost a lock that Leo's new hire works in Product Development and is spearheading the deal making process that is taking place. For Leo to announce his/her title in a PR would have let the cat out of the bag. Something really good is happening. This person didn't get a sign on bonus and I'm sure a nice salary to sit in the Wakefield Virtual office reading the IHUB message board. The IPIX 2022 TRANSFORMATION is about to happen.
Have Faith longs. Things are about to change in a big way.
Leo's new hire is key. Our Patience will be well rewarded.
IMO we get an OM deal and some asset swaps in a separate deal.
Apparently the 20+ virus test results must have opened a few eyes and pocketbooks.
With 20 or so cda's I'd say that BIG Pharma understands the pipeline!!!
Expect a B deal anytime soon. LOVE to see Leo release it on the weekend.
There would be lots of posters here changing their underwear come Monday morning.
A HUGE B deal is a brewing. No bout a doubt it...
As far as all the fudsters here go...pffffff!
tic toc tic toc
Seems to me that shorts and gang are taking advantage of Innovation's quiet period. Leo can't put out a PR or even a Blog.
tide is about to turn...Tic Toc
BooDog I agree. I think leo is gonna tinkle on all these fudsters who have worked 168 hours a week for the last 2 months with their repetitive BS nonsense to keep the price down.
No warning PR this time!! Just KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!!!!
KFCYAHOO What in GOD's name are you talking about?
Cabel's post from Leo was about PRURISOL not OM.
sheeeeeeesh!
Noretreat the only way to lose money is if you sell and if you sell you are not a stockholder and there for you can't attend the STOCKHOLDERS meeting.
You are so BRILLIANT! Keep your advice....
SCOTTWNY I think Dr. Bertolino answers your question whether 2 patients was sufficient in the 9/14/2017 PR Below.
Looks like 1 out of 10 would have been sufficient but 2 out of 2...
1st 2 hitters up knocked it out of the Park.
Something NO other Pharma has ever done without side effects.........JUST WOW!!!!!!!!!!!
September 14, 2017
Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
Kevetrin
BEVERLY, Mass., Sep. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that a new clinical site has been added in the Company’s Phase 2 clinical trial of Kevetrin for ovarian cancer. The site, a renowned academic medical center, is now actively enrolling patients.
In the interventional study, Kevetrin, Innovation Pharmaceutical’s novel p53-modulating drug candidate, is being evaluated in patients with platinum-resistant/refractory ovarian cancer. The primary outcomes for the study are incidence of treatment-emergent adverse events and evaluation of changes in cancer pathway biomarkers and molecular signatures, as measured in tissue/tumor samples pre-treatment and after three weeks of treatment.
“What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
Initial preliminary study results are anticipated in 4th quarter 2017.
JNJ will be the BIG player for a BIG Brilacidin deal.
They have seen what it can do 1st hand as a biofilm for their medical devices unit.
Just look at the IPIX website below. IPIX is not testing biofilms and yet there it is SMACK in the middle of the B circle.
If JNJ didn't see positive results well it sure wouldn't be listed.
JNJ just needs "ANY" approval of B and they can just file some paperwork and use B as a Biofilm. No trials need to be run.
JNJ will do what ever to speed a trial up to get that approval.
http://www.ipharminc.com/therapeutic-areas/
and none of this imo....It's FACT!!!!
Gonna miss those daily "This POS is going Down" messages every morning..
With Bertolino basically calling the shots I bet we DO NOT get a PR for the Unblinding...Just results BAM!
Just like Leo did for the "215" patient 3 dosages double blinded ABSSSI trial. No unblinding pr just last person enrolled pr then a results pr in "9" weeks.
9 weeks? Hmmmm that's today for Prurisol...
tic tic tic tic tic tic
PS Groron you are still FOI!
WHAT? " Mgmt would be wrong to partner anything without knowing value of P.
Where do you come up with this stuff?
How will they know the value of PRURISOL just from a psoriasis trial?
You forget about psoriatic arthritis and other uses?
You need to follow georgii postings a little closer.
ATTENTION ATTENTION ATTENTION EVERYONE THIS IS GROTON68 SPEAKING
Groton68 So then, all these Pharma's with CDA's on B and K are just wasting their time along with Leo until P results are out. Where do you come up with this stuff.
I assume you just post it for attention.
It's obvious IPIX is now a PURE CLINICAL Stage Pharma company.
NO pre-clinical employees needed. Thus the Prez of Research who is also a director takes a paycut.
ANy future pre clinical will be done by BP.....Sheeeeeeesh!
Rdunn88 looks to me like you can't even count
P Phase2a last patient visit March 14 2016
P Phase2a results May 24 2016
More like 10 weeks.NOT 5 weeks.....But hey keep up the good work ss appreciates it.
Cabel that is not correct.
It's less than 20 since some Pharma's are interested in more than 1 drug or indications.
KFC...You don't know the Bunny Leo history from Leo's old employer
10 or so years ago?
TheBunny Wednesday, 06/18/08 05:47:35 PM
Re: Ubertino post# 13210 0
Post #
13211
of 137789 Go
I didn't quibble and paid $2.20 to $3.50 for mine and held it all this time...cause I knew in my bones it's a winner.
Just wish I could have bought a ton of it under a buck but todays price is CHEEEP!
This company hasn't even started a clinical trial EVER!!!!!!
LMFAO@BUNNY!!!!
Sounds like something rdunn88 would post here...
Oh say it ain't so!!!!!
You need to do your homework a little better...
BEVERLY, Mass., March 03, 2017
As background, pre-clinical work determined the bioavailability of Kevetrin was 79 percent when given orally in Sprague-Dawley rats. To further establish the efficacy of oral Kevetrin, in vivo mouse studies were carried out in an ascites ovarian tumor model using OVCAR-3 and OV-90 tumor models, both of which possess different mutant p53 genes. Importantly, these pre-clinical results showed that the overall efficacy of Kevetrin was similar across both oral and intraperitoneal routes of drug administration.
BooDog We are not waiting on full data for a Brilacidin deal.
The CDA people have what they requested. This is from Leo's 1/16/2018 PR.
IMO Any day or week now:)
What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership/licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”
Bertolino Sept. 2017........
“What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
I'm in 100%. To each his own.
Sorry but you aren't getting me to sell with that 5% crap.
NOT with this GEM!!!
Daubers I'm with you.
A couple BILLION up front for B and 50/50 sales on ALL current and future indications. 1 Pharma 1 MEGA deal.
3 B drugs heading in to phase3 in BILLION dollar indications warrants a HUGE up front payment.
KMBJN Kevetrin Oral Pre-clinical
March 3, 2017
Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
Kevetrin
BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to update shareholders on continuing efforts to develop the oral dosing of Kevetrin.
Based on positive results from Cellceutix’s Phase 1 trial of Kevetrin in solid tumors conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, the Company is moving forward with a Phase 2 trial of intravenously-administered Kevetrin in patients with late-stage, platinum-resistant ovarian cancer. Cellceutix has decided to pursue an oral formulation for Kevetrin to improve patient convenience and potentially increase therapeutic efficacy given the drug’s short half-life and other pharmacokinetics, as discussed below.
As background, pre-clinical work determined the bioavailability of Kevetrin was 79 percent when given orally in Sprague-Dawley rats. To further establish the efficacy of oral Kevetrin, in vivo mouse studies were carried out in an ascites ovarian tumor model using OVCAR-3 and OV-90 tumor models, both of which possess different mutant p53 genes. Importantly, these pre-clinical results showed that the overall efficacy of Kevetrin was similar across both oral and intraperitoneal routes of drug administration.
Cellceutix has initiated a series of GLP (Good Laboratory Practice) studies to assess the safety of Kevetrin given orally. Considering that Kevetrin is a non-cytotoxic drug, our intent, with FDA permission, is to next proceed with a Phase 1 clinical trial in healthy volunteers using the oral route. These studies are being conducted by approved vendors and include: photosafety testing, pharmacokinetics, in vivo metabolism, metabolic stability, protein binding, and genetic and physiological toxicology reports.
Preliminary data analyses in a pharmacokinetic study in rats revealed a half-life of approximately 1 hour and a clearance of 78ml/min/kg for both oral and intravenous (IV) dosing. Results of an initial photosafety study demonstrated a molar extinction coefficient value of less than 5 L/mol*cm over a range of wavelengths above 290 nm, well below the 1000 L/mol*cm limit stated in ICH guidelines—indicating Kevetrin has no phototoxicity. A preliminary toxicity study showed that at doses up to 500 mg/kg given orally daily for 7 days, Kevetrin was well-tolerated by the rats as indicated by an 11 percent increase in body weight and no abnormal clinical observations. Further, this dose was greater than the doses used in the preclinical efficacy study. Remaining safety studies will be completed in the second half of this year.
In related news: Last week, Cellceutix research partners in Italy shared results with the Company from their ongoing preclinical work evaluating Kevetrin in Acute Myeloid Leukemia (AML), Pancreatic Cancer and human Gliobastoma Multiforme (hGBM). The data will be presented (by them) at scientific conferences, and is consistent with, and further informs, our knowledge of Kevetrin. Also, efficacy data from the 2nd cohort in the Brilacidin-Ulcerative Colitis proof-of-concept study is in the last stage of being compiled by the CRO and, following a final review, will be released.
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction.
pssssss...BTD or PRIME(uk)...or both....
The brand name is Entyvio(iv). check the link out.
https://www.entyvio.com/frequently-asked-questions
Blues44 got up early. Must be working this weekend
Cabel....Sure they do. Read on...
http://www.clinicalconnection.com/study-details/36999/psoriasis---berlin-nj?res=36999
plentyp that's 35 days....5 weeks.....tic tic tic tic tic..
KABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM!!!